Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06504446 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
A Phase 2 study of Refractory or Unexplained Chronic Cough, sponsored by Nocion Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 455
- Enrollment target
- 20
- Study locations
NCT06504446 is a Phase 2 study of Refractory or Unexplained Chronic Cough that is actively recruiting participants, run by Nocion Therapeutics. The registered enrollment target is 455 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT06504446, a Phase 2 study of Refractory or Unexplained Chronic Cough, is actively recruiting participants, sponsored by Nocion Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 455 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG NOC-110
Study Locations (20)
California
- So Cal Clinical Research - Huntington Beach
- Allergy and Asthma Associates of Southern California dba Southern California Research - Laguna Niguel
- Paradigm Clinical Research Centers, LLC - Modesto - Modesto
- NewportNativeMD,Inc - Newport Beach
- Center for Clinical Trials, LLC - Paramount
- Paradigm Clinical Research Centers, LLC - Redding
- DaVinci Research LLC. - Roseville
- Allergy & Asthma Associates of Santa Clara Valley - San Jose
- California Allergy & Asthma Medical Group Inc. - San Jose
- Allergy, Asthma, and Immunology Medical Group - Ventura
- Allergy and Asthma Clinical Research Inc - Walnut Creek
Florida
- Innovative Research of West Florida, Inc. - Clearwater
- Omega Research Debary, LLC - DeBary
- Jacksonville Center for Clinical Research - Jacksonville
- Clinical Site Partners, LLC Leesburg dba Flourish Research - Leesburg
Arizona
- Medical Research of Arizona - Scottsdale
- AMR Phoenix - Tempe
Alabama
- G & L Research, LLC - Foley
Arkansas
- Little Rock Allergy & Asthma, P.A. Clinical Research Center - Little Rock
Colorado
- Lynn Institute of Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2024-09-24 |
| Est. Completion | 2026-04-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06504446
The ClinicalTrials.gov registry entry for NCT06504446 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nocion Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory or Unexplained Chronic Cough appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06504446 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06504446 about?
NCT06504446 is a clinical study titled "Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough". This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
What is the current status of trial NCT06504446?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 455 participants. The study started on 2024-09-24. Estimated completion is 2026-04-10.
What conditions does trial NCT06504446 study?
This clinical trial studies the following conditions: Refractory or Unexplained Chronic Cough.
What interventions are being tested in trial NCT06504446?
The interventions under investigation include: Placebo (OTHER), NOC-110 (DRUG).
Who is sponsoring clinical trial NCT06504446?
This trial is sponsored by Nocion Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06504446 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.